

# EURO DURG bulletin

No. 7

April 1999

**EUROPEAN DRUG UTILIZATION  
RESEARCH GROUP**

*Editors. This issue was prepared by the following members of the Executive Committee of EURO DURG: Morten Andersen, Robert Vander Stichele, and Ulf Bergman.*

## **EURO DURG Annual Meeting in Jerusalem : October 1 – 3, 1999**

### **See you this year in Jerusalem!**

Two years ago in Berlin, we decided to follow the European Association of Clinical Pharmacologists to join them in organising the 1999 conferences in Jerusalem.

The EACPT meeting will run from Sunday evening, October 3 till October 8, in the city of Jerusalem.

The EURODURG meeting will precede this and run from Friday evening, October 1, till Sunday evening, October 3, in a resort on the Dead Sea, 30 minutes from Jerusalem.

There will be a joint session on Drug Utilisation Research on Monday, October 4, with EURODURG, EACPT and WHO-EURO, with the DUR-posters also concentrated on that Monday.


The EURODURG meeting in the first weekend of October will be a very interesting scientific meeting. You will find the promising preliminary program in the inner pages of this bulletin. We managed to bring together a bewildering mix of tutorials, workshops and presentation sessions, chaired by eminent scholars in the field. Look carefully at the program, it will help you to

make the decision to come to Israel and to join us all for this event. We expect a large delegation of Israeli Eurodurgers

to attend, so this will be a unique opportunity to meet the scientists of this country.

Some of you have sent posters to the EACPT. These posters will be **automatically** considered for selection as a oral presentation at the EURODURG meeting. In addition, you can send in other posters, directly to EURODURG (see call for abstracts in this bulletin). Look carefully at the titles of the sessions in the scientific program. It will stimulate you to participate and send in your research as an abstract. The chairs of the sessions will examine the relevant EACPT abstracts and the abstracts you have sent directly to EURODURG. Your message can then be integrated in the session, as a presentation or as part of the tutorial.

We hope to see you in Israel, next October. Join us for an interesting meeting, join us in the informal contacts of the social program, and join us in the working groups of EURODURG, who all will briefly present their activities of the passed year.



### **Prof. Flora Haaijer-Ruskamp Chair EURODURG Chair**

Prof. Flora Haaijer-Ruskamp (The Netherlands)  
Tel: +31-50-363-32-16  
Fax: +31-50-363-30-82  
e: F.M.Haaijer-Ruskamp@med.rug.nl

### **Vice chair**

Dr. John Ferguson (UK)\*

### **Secretary**

Marit Rønning (Norway)\*

### **Treasurer**

Dr. Emilio Sanz (Spain)\*

### **Vice treasurer**

Dr. Morten Andersen (Denmark)  
Tel: +45 65503791  
Fax: +45 65916089  
e-mail: m-andersen@cekfo.ou.dk

### **Members**

Prof. Ulf Bergman (Sweden)\*

Dr. Frantisek Perlik (Czech Republic)  
Tel: +420-2-2496-3118  
Fax: +420-2- 297-932  
e-mail: fperl@dec52.lfl.cuni.cz

Dr. Zsuzsanna Szepezdi (Hungary)\*

Dr. Robert Vander Stichele (Belgium)  
Tel: +32 9 240 33 36  
Fax: +32 9 240 49 88  
e: Robert.VanderStichele@rug.ac.be

Dr. Almar Grimsson (Iceland)\*

Dr. Joerg Hasford (Germany)\*

\*Phone, fax and e-mail found on the last page.

### **IN THIS ISSUE**

- **Invitation for the meeting in Jerusalem** p. 1
- **Scientific Program for the meeting in Jerusalem** p. 2-4
- **Registration form for the Jerusalem Meeting** p. 5
- **Call for abstracts** p. 6
- **The Joint Session EACPT /EURODURG /WHO** p. 7
- **The EURODURG web site** p. 7
- **UK-DURG 1998 meeting in London:  
Growth promoters in animals and  
human resistance to antibiotics.** p. 7
- **Update on National DURG groups in Europe** p.8

# EURODURG Annual Meeting : International Symposium:

## Improving the quality of drug utilisation: resources, methods, and objectives

**ISRAEL, October 1- 3, 1999**  
**THE GRAND NIRVANA HOTEL, Mobile Post Dead Sea**

### *In collaboration with:*

*WHO-EURO, WHO Collaborating Center for Drug Statistics and Methodology, Israel-DURG*

### *Satellite symposium to the:*

*3rd congress of the European Association for Clinical Pharmacology and Therapeutics*

*4th Jerusalem Conference on Pharmaceutical Sciences and Clinical Pharmacology*

### **SCIENTIFIC COMMITTEE :**

J. Hasford, Ferguson, A. Grimsson, F. Haaijer-Ruskamp, R. Vander Stichele, U. Bergman, E. Sanz

### **LOCAL ORGANISER :**

H. Reuveni

## **SCIENTIFIC PROGRAM**

### **Friday, October 1, 1999**

---

18.00 h: Arrival of the delegates

### **Saturday, October 2, 1999**

---

#### **Morning**

#### **(Track 1)**

#### **(Track 2)**

08.30 - 09.00:

Welcome and opening speech  
*(Prof. F. Haaijer-Ruskamp)*

09.00 - 10.30:

Clinical versus administrative  
 databases of drug use :  
 Limitations in content and  
 purposes  
**Chair: Prof. J. Hasford**  
*(Presentations + discussion)*

Educational approaches  
 to enhancement  
 of prescribing quality:  
 Comparison of methods  
**Chair: Emilio Sanz**  
*(Presentations + discussion)*

11.00 - 12.30:

Collecting qualitative and  
 quantitative data on the use of  
 antibiotics for international  
 comparison. The DUR response  
 to the European «microbial treat».  
**Chair: Almar Grimsson**  
*(Presentations + discussion)*

Organisational approaches  
 to enhancement of  
 prescribing quality:  
 disease management at work.  
**Chair: N. Freemantle**  
*(Presentations + discussion)*

---

Afternoon	(Track 1)	(Track 2)
14.00 - 15.30	Board meeting	Speakers corner Poster walking tour
16.00 - 17.30	Variability in prescribing: the value of small area research <i>Chair: John Ferguson</i> (Tutorial)	Methods in evaluating efforts to enhance prescribing quality: Process and product evaluation on micro and macro level <i>Chair: Flora Haaijer-Ruskamp</i> (Workshop)

---

**Sunday, October 3, 1999**


---

Morning	(Track 1)	(Track 2)
09.00 - 10.30:	Qualitative approaches to the study of antidepressant utilisation by patients <i>Chair: K. Bingefors</i> (presentations + discussion)	Mapping national drug lists into the new European standard for medicinal product identification (CEN-ENV 12610) and linkage to ATC-DDD <i>Chair: R. Vander Stichele, M. Levy</i> (Tutorial)
11.00 - 12.30:	Capturing data on patient's drug utilisation in the absence of databases: modern tools for Stone Age conditions <i>Chair: J. Hallas, H. Reuveni</i> (Presentations + discussion)	Free paper session <i>Chair: N. Montanaro</i> (Presentations + discussion)
Afternoon	(Track 1)	(Track 2)
14.00 - 15.30	Action programmes, BIOMED 5 <sup>th</sup> framework, Eastern Europe collaboration, international trusts: a guided tour to fund raising for quantitative and qualitative research proposals <i>Chair: Kees De Joncheere / Flora Haaijer-Ruskamp / Deanna Trakas</i> (Workshop)	
16.00 - 17.30	Technical and organisational solutions for preserving privacy in postmarketing surveillance and drug utilisation research <i>Chair: A. Bertelsmann</i> (Presentations + discussion)	Between efficacy and efficiency: the role of pharmaco-kinetics, patient compliance, and subjective risk/benefit perception <i>Chair: Prof. J. Urquhart</i> (Tutorial)
17.30- 18.00	Wrapping up	
18.00	Departure for EACPT-meeting in Jerusalem	

---

## PRACTICAL ARRANGEMENTS FOR THE TRIP TO ISRAEL

### Venue

The Grand Nirvana Hotel  
Mobile Post Dead Sea  
Israel 84960

### Information

Reuveni Haim, Local Congress Organizer  
Soroka Medical Center, Department of Pediatrics,  
Beer Sheva, Israel  
Tel: +972 52 763666  
Fax: +972 7 640 33 18  
E-mail: Reuveni@bgumail.bgu.ac.il

### Conference Fee

#### 450 EURO

(50 EURO extra for registrations after August 15)

Including:

- Shuttle bus from Tel Aviv and to Jerusalem
- Hotel room for 2 Friday and Saturday night
- Breakfast, lunch, dinner, coffee breaks
- Social Program
- Full attendance to the scientific meeting.

### Rebate

A 150 Euro rebate per person is possible, for students and participants from Eastern European countries

### Money Transfer

Is possible by Credit Card (Visa, Diners or American Express) or by bank transfer (see registration form for details).

### Hotel

Reservations for Friday and Saturday night in Grand Nirvana Hotel are included in the registration form. Please add a note to your registration form for Haim Reuveni, if you do not want to stay in the hotel or need additional nights or if you are accompanied by one or more partners, not attending the conference.

### Transportation

There will be a bus shuttle on Friday afternoon and Friday evening from Tel Aviv International Airport to the Grand Nirvana Hotel. Arrival on Friday is strongly recommended, as the next day is Sabbath day. Further details on the shuttle service will be sent with the confirmation of your registration.

### Call for Abstracts

All abstracts sent to the EACPT meeting are eligible for oral presentation at the Eurodurg meeting (*However, you have to register and pay separately for the EURODURG meeting*).

Other abstracts can also be sent directly to EURODURG and will be reviewed by the scientific committee. Use the abstract form on page 6. The deadline for abstracts is June 15, 1999

### Liaison with EACPT congress

A combination of two congresses is possible and will interest many of the delegates. The EACPT congress is held, immediately after the Eurodurg symposium. Organized transportation from the Dead Sea will be arranged.

On Monday, October 4, the joint EACPT-EURODURG session on Drug Utilization is organized, as well as the joint poster session. It is possible to register for one day at the EACPT meeting. Information can be sought at <http://www.kenes.com/eacpt3/>

**Consult the EURODURG web site regularly  
for additional information on the ANNUAL MEETING  
<http://www.eurodurg.org/>**

**REGISTRATION FORM**  
**EURO DURG ANNUAL MEETING – SCIENTIFIC SYMPOSIUM**  
**Israel, October 1-3, 1999**

**Please complete this form and return this, together with your payment to**

Dr. Haim Reuveni  
 Israel DURG  
 Soroka Medical Centre, Department of Pediatrics , Beer- Sheva, Israel  
 Tel: +972 52 763 666 Fax:+972 7 640 33 18 E-mail: Reuveni@bgumail.bgu.ac.il

**Identification**

Please complete this section accurately: the information you provide allows us to correspond with you efficiently, and it will also be used for your badge and the participants' list in the meeting.

**Participant (Please TYPE or PRINT IN BLOCK LETTERS)**

Name: \_\_\_\_\_

First Name (and/or initials) \_\_\_\_\_ Title (Prof, Dr, Mr, M, Ms) \_\_\_\_\_

Address: \_\_\_\_\_

Tel. : \_\_\_\_\_ Fax: \_\_\_\_\_ E-mail: \_\_\_\_\_

**Registration Fee (450 EURO)**

(Rebate of 150 EURO possible for students and EEC-countries)

(Add 50 EURO for registrations after August 15, 1999)

(Israeli participants can register first, and will then receive payment information and a request for fee from H. Reuveni)

**Payment option 1 : Credit card**

ÿ VISA      ÿ DINERS      ÿ AMERICAN EXPRESS

Number \_\_\_\_\_ Expiry Date (month, year) \_\_\_\_\_

Surname (as shown on card) \_\_\_\_\_ First Name \_\_\_\_\_

Signature \_\_\_\_\_ Date (day, month, year) \_\_\_\_\_

**Payment option 2: Bank Transfer (only in EURO)**

State your name and address clearly indicated (so that we can identify the sender)

If payment is made for more than one person, please make sure that all names are indicated and send fully completed registration forms together with a copy of the bank transfer.

DRAFTS PAYABLE TO : EURO-DURG

BANK NAME: Bank Bilbao Vizcaya

POSTAL ADDRESS: Weyler Square, 4, E-38004 Santa Cruz de Tenerife, Spain

ACCOUNT NUMBER: 0182 – 5801 – 16 – 001505657 (EURO-DURG VAT Number is G38420386)

REASON PAYMENT: Registration Fee Annual Meeting EURO-DURG

Date \_\_\_\_\_ Signature \_\_\_\_\_

**Cancellation Policy**

Postmarked before September 1, 50 % refund, after September 1, no refund.

**ABSTRACT FORM**  
**EURO DURG ANNUAL MEETING – SCIENTIFIC SYMPOSIUM**  
**Israel, October 1-3, 1999**

**Presenting Author Details**

Family name \_\_\_\_\_

First name \_\_\_\_\_ Title (Prof, Dr, Mr, Mrs) \_\_\_\_\_

Institution \_\_\_\_\_

Address \_\_\_\_\_

Tel.: \_\_\_\_\_ Fax. : \_\_\_\_\_ E-Mail : \_\_\_\_\_


**Deadline**

June 15, 1999

Type single spaced in black with a 12 pitch character, no paragraphs. Use full width of frame, do not type outside frame. Type TITLE in capital letters in top space, type Name(s), or author(s), (with presenting author underlined), in middle space. Type body text of abstract in lower space.

**Abstract to be send to:**

Dr. Haim Reuveni  
 Israel DURG  
 Soroka Medical Centre,  
 Department of Pediatrics  
 Beer-Sheva  
 Israel  
 Fax: + 972 7 640 33 18

Date \_\_\_\_\_

\_\_\_\_\_  
Signature

## RESISTANCE TO ANTIBIOTICS

*EURODURG has been following closely the developments on the European level concerning antibiotic resistance.*

*At UK-EURODURG Annual meeting 1998 in May last year, the issue of the relation with growth promoters in animal farms was raised by Lord Soulsby.*

*The redaction wanted to provide the readers of this bulletin with a copy of the meeting report as it appeared in the Pharmaceutical Journal :*

**Making growth promoters POM would help, veterinary Persays**

Giving growth promoters prescription only status would help the situation of antibiotic resistance, according to Lord Soulsby of Swaffham Prior (chairman, House of Lords Select Committee on Science and Technology report on antibiotics [*PJ*, May 2, 1998, p. 617]).

Speaking at the United Kingdom Drug Utilisation Research Group annual scientific meeting, held in London on December 11, 1998, Lord Soulsby, a veterinarian, said that the use of growth promoters in animals was an area of particular concern in light of the increasing reports of resis-

tance to antibiotics. Growth promoters were sub-therapeutic doses of antibiotics which, when added to animal feeds, could increase an animal's daily growth rate by 3 to 10 per cent. They were merchants list products and therefore they could be obtained easily in animal feeds. The mechanism by which increased growth was achieved was unclear. One theory suggested that antibiotics stopped the commensal bacteria in the gut of the animal from absorbing nutrients from food, therefore more nutrients were available for absorption by the host.

Antibiotic resistance in animals was not as serious as it was in humans but it was still a serious concern. Caution as to growth promoter use in animals was advised more than 30 years ago in the Swann report but little attention had been paid to this, Lord Soulsby said.

Asked how irresponsible prescribing of antibiotics in animals could be stopped, Lord Soulsby said that the British Veterinary Association had produced prescribing guidelines but easy access to growth promoters was still a problem. Another problem was the illegal importation of drugs via the internet. Drugs were being purchased at cut prices without detailed instructions as to their use.

There was a global pool of resistant organisms, said Lord Soulsby. The horticultural, agricultural, veterinary and human use of antibiotics and the use of antibiotics in fish farming and effluent treatment all added to the pool of resistant organisms. The links be-

tween animal antibiotic use and antibiotic resistance in humans was not clear. There was evidence that people who worked with animals, eg turkey farmers, shared the same commensal gut organisms as the animals, indicating that close contact might play a part in the spread of antibiotic resistance to humans.

Lord Soulsby highlighted the background to *Salmonella typhimurium* DT104 resistance. Resistant strains were first isolated in cattle in 1998. By 1990, resistance was found in other human food chain animals, such as horses, chicken and sheep. In 1991, it was found in cats and in 1996, it was isolated in reptiles. Because cats and reptiles were kept as household pets, there was the threat of the resistant organisms infecting humans.

The need for prudent use of antibiotics was now recognised, Lord Soulsby said. The European Union had already planned to ban the use of four antibiotics as growth promoters, but he hoped that codes of conduct would be formed. There was a progressive increase in resistance to common antibiotics such as sulphonamides, streptomycin, tetracyclines, chloramphenicol and trimethoprim.

*The Pharmaceutical Journal (vol. 262), January 2, 1999.*

### Program of the Joint EURODURG-EACPT Session Drug utilization in quality assessment of drug therapy.

Monday, October 4, 1999 (morning session)

Co-chairpersons : J. Hasford, M. Bogaert

- J. Hallas. Drug related hospital admissions: the ultimate outcome measure for prescribing quality
- R. Vander Stichele. Drug intake omissions and their consequences
- J. Ferguson. Variations in evidence based prescribing. Implications for Drug Utilisation Research.
- N.S. Freemantle. Effective interventions to optimize prescribing quality

### Drug Utilization Research Poster Session

Monday, October 4, 1999, afternoon

## VISIT THE EURODURG WEBSITE

<http://www.eurodurg.org/>

- Read our constitution
- Read the back issues of the bulletins
- Read our mission statement
- Find updated addresses of board members
- Find out the latest about upcoming congresses

**An update of National  
DURGs in Europe  
Chairs and/or  
contact persons also to be found on  
our web page:  
<http://www.eurodurg.org>**

**BELGIUM: B-DURG**

Denise Walckiers, pharmacist  
Scientific Institute of Public Health – Louis Pasteur  
Wytzmanstreet, 14  
B-1050 Bruxelles  
Tel: +32 2 642 50 35; Fax: +32 2 642 5410  
e-mail: [denise.walckiers@iph.fgov.be](mailto:denise.walckiers@iph.fgov.be)

**CZECH REPUBLIC: Czech-DURG**

Dr. Vladimír Biba  
State Institute for Drug Control - SUKL,  
Srobarova 48  
100 41 Prague 10, Czech Republic  
Tel: +420 2 67 08 28 90; Fax: +420 2 744 944  
e-mail: [stika@sukl.cz](mailto:stika@sukl.cz)

**DENMARK: The Danish Society for Pharmacoepidemiology**

Anna B Almarsdottir, PhD  
Dept. of Social Pharmacy  
Universitetsparken 2  
DK-2100 Copenhagen, Denmark  
Tel: +45 35 370 850; Fax: +45 35 372 621  
e-mail: [annalm@mail.dfh.dk](mailto:annalm@mail.dfh.dk)

**GERMANY: Gesellschaft für Arzneimittelnwendungsfor-**

schung und Arzneimittel-epidemiologie (GAA) e.V.  
Prof. Joerg Hasford  
The Biometric Centre for Therapeutic Studies  
Pettenkoferstrasse 35  
D-81377 Munich, Germany  
Tel: +49 89 7095 7481 Fax: +49 89 7095-7482  
e-mail: [Has@ibe.med.uni-muenchen.de](mailto:Has@ibe.med.uni-muenchen.de)

**GREECE: DURG GR**

Dr. A. Iliopoulou  
Section of Clinical Pharmacology,  
Dept. of Clinical Therapeutics  
Athens University, Alexandra Hospital 80  
Vas Sofias Str 115 28  
Athens, Greece  
Fax: +30 1 7771 731  
e-mail: [ailiop@atlas.uoa.gr](mailto:ailiop@atlas.uoa.gr)

**HUNGARY: DURG-Hungary**

Dr. Zsuzsanna Szepezdi  
National Institute of Pharmacy  
Budapest, 1051 Zrínyi u.1-3., Hungary  
Tel: +36 1 3177-113; Fax: +36 1 318 1167

**ICELAND: IS DURG**

Almar Grimsson  
The Icelandic Pharmaceutical Society Iceland  
Tel: +354 5553 569; Fax: +354 555 3561  
e-mail: [albas@itn.is](mailto:albas@itn.is)

**ISRAEL: ISRAEL DURG**

Prof. Micha Levy, M.D  
Dept. of Medicine  
Hadassah University Hospital  
Jerusalem 91-120, Israel  
Tel: +972 2 6776 449; Fax: +972 2 6422 384  
e-mail: [rach;Error!Marcador no definido.](mailto:rach;Error!Marcador no definido.)

**ITALY: DURG-Italia**

Dr. Alberto Vaccheri  
University of Bologna  
Department of Pharmacology  
Via Innerio 48  
I-40126 Bologna, Italy  
Tel: +39 51 248526; Fax: +39 51 248862  
e-mail: [vaccheri@biocfarm.unibo.it](mailto:vaccheri@biocfarm.unibo.it)

**NORWAY: DURG NO**

Marit Rønning  
Norsk Medisinaldepot AS  
WHO Collaborating Centre for Drug Statistics Methodology  
PO Box 100, Veitvet  
N-0518 Oslo 5, Norway  
Tel: +47 22 16 98 10 (direct)/169600 (general)  
Fax: +47 22 16 98 18  
e-mail: [Marit.Ronning@nmd.no](mailto:Marit.Ronning@nmd.no)

**SPAIN: DURG-ESPAÑA**

Dr. Emilio Sanz  
University of La Laguna  
Clinical Pharmacology  
School of Medicine  
La Laguna, Tenerife, 38071, Spain  
Tel: +34 922 319347; Fax: +34 922 655 995  
e-mail: [esanz@ull.es](mailto:esanz@ull.es)

**SWEDEN: The Swedish Society for Pharmacoepidemiology**

Dr. Ulf Bergman  
Department of Clinical Pharmacology  
Karolinska Institute  
Huddinge University Hospital  
Huddinge S 141 86, Sweden  
Tel.: +46 8 58 58 11 96; Fax: +46 8 58 58 10 70  
e-mail: [Ulf.Bergman@pharmlab.hs.sll.se](mailto:Ulf.Bergman@pharmlab.hs.sll.se)

<http://www.labtek.ki.se/slef>

**THE NETHERLANDS: NL-DURG**

Dr. R.M.C. Herings  
University of Utrecht  
Dept. of Pharmacoepidemiology  
Faculty of Pharmacy  
PO Box 800082  
3508 TB Utrecht, The Netherlands  
Tel: +31 30 253 7325; Fax: +31 30 253 9166  
e-mail: [R.M.C.Herings@far.ruu.nl](mailto:R.M.C.Herings@far.ruu.nl)

**UNITED KINGDOM: DURG-UK**

Dr. John Ferguson  
Medical Director  
Prescription Pricing Unit  
Bridge House  
152 Pilgrim Street  
Newcastle upon Tyne NE1 6SN, UK  
Tel: +44 191 2035352 (direct) +44 191 2325371 (general)  
Fax: +44 191 2035499  
e-mail: [ferguson\\_john@ppa.nhs.uk](mailto:ferguson_john@ppa.nhs.uk)